

Special Issue

Natural and Synthetic Molecules with Anticancer Activity: Pharmacological Basis and Mechanistic Insight

Message from the Guest Editors

Cancer is one of the most challenging health problems encountered humanity. The deleterious side-effects and development of resistance to the current clinically used chemotherapeutics necessitate continuing research to better understand the pathology of the disease and design more effective therapeutics. Natural products with defined molecular compounds or their semisynthetic derivatives have been well-documented for their potent antitumor activity, such as paclitaxel, vincristine, doxorubicin, and bleomycin. Furthermore, another approach is ligand-based anticancer drug discovery, which relies on the screening of mega libraries of chemically diverse synthetic molecules against relevant targets, while the structure-based approach involves the rational design and synthesis of biomolecules to optimize their binding to a validated macromolecular target of a known 3D molecular architecture. In this context, this Special Issue is aimed at encouraging scientists in the field of anticancer drug development to publish their recent finding on the mechanistic mode of action of defined natural, semisynthetic, and synthetic biomolecules with emphasis on their anticancer molecular pharmacology.

Guest Editors

Dr. Hassan Ebrahim

Department of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Louisiana Campus, Monroe, LA 71203, USA

Dr. Angela-Patricia Hernández

Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca, Campus Unamuno s/n, 37008 Salamanca, Spain

Deadline for manuscript submissions

closed (30 June 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/181406

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).